Cytokinetics
CYTK
178 hedge funds and large institutions have $1.51B invested in Cytokinetics in 2020 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 59 increasing their positions, 57 reducing their positions, and 42 closing their positions.
115% more call options, than puts
Call options by funds: $14.3M | Put options by funds: $6.65M
5.43% more ownership
Funds ownership: 97.6% → 103.03% (+5.4%)
4% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 57
3% more capital invested
Capital invested by funds: $1.47B → $1.51B (+$41.6M)
7% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 42
2% less funds holding
Funds holding: 181 → 178 (-3)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$45M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$38.4M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$37.8M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$28.4M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$17.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$55.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$42.4M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$32.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$22M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$16.2M |
CYTK Hedge Fund Activity: Q4 2020 in Review
178 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q4 2020, worth a combined $1.51B — up 2.8% from $1.47B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of CYTK and 39 opened new positions — a net loss of 3 holders — while 57 trimmed existing stakes and 59 added.
The largest buyer was Deerfield Management, opening a new position worth an estimated $45M. The largest seller was Great Point Partners, exiting entirely with an estimated $55.2M sold.
- 178 institutional investors held Cytokinetics (CYTK) as of Q4 2020, down from 181 in Q3 2020.
- Funds reported $1.51B of Cytokinetics stock for Q4 2020, up 2.8% quarter-over-quarter.
- 39 funds opened new Cytokinetics positions in Q4 2020 and 42 closed out, a net change of -3 holders.
- The largest Cytokinetics buyer in Q4 2020 was Deerfield Management, an estimated $45M added.
- The largest Cytokinetics seller in Q4 2020 was Great Point Partners, an estimated $55.2M sold.
Based on aggregated 13F filings for Q4 2020.